Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activation of dendritic cells via damage-associated molecular patterns (DAMPs) describes the process by which endogenous molecules released from stressed or damaged cells (such as HMGB1, ATP, and uric acid) are recognized by pattern recognition receptors (e.g., Toll-like receptors, NOD-like receptors) on dendritic cells. This interaction drives dendritic cell maturation, enhances their antigen-presenting capacity, and promotes pro-inflammatory cytokine production, playing a crucial role in bridging innate and adaptive immunity. This process is fundamental in host defense, sterile inflammation, autoimmunity, transplant rejection, and antitumor responses. Overall, "Dendritic cell activation via damage-associated molecular patterns" is a pathway/process, not a discrete molecular target, and is best described in the context of the key receptors involved (such as TLR4 or NLRP3) and the DAMP ligands they recognize.
Drugs targeting TLRs or downstream cytokines may blunt dendritic cell activation/maturation in response to DAMPs. Some experimental therapies block specific DAMPs (e.g., HMGB1 antagonists) or PRRs.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dendritic cell activation via damage-associated molecular patterns.